Jaclyn Henderson, PhD

Advisor

Jaclyn Henderson is an Advisor at Raven, focusing on new company creation. Jaclyn joins Raven from Arclight Therapeutics where as VP Early Discovery, she was responsible for developing a diverse portfolio of early-stage assets across neurodegenerative diseases. Her prior roles include Pfizer, Biogen, Vertex and Jnana Therapeutics. During her career, she has worked on developing four clinical stage compounds across several therapeutic areas including Parkinson’s Disease, and Phenylketonuria. Jaclyn holds a PhD in Organic Chemistry from the University of Edinburgh and completed her undergraduate studies at the University of Aberdeen.